Table 2 Clinical effect of HDF, mortality
Study [Ref] | Study design | Modality/number | Results |
|---|---|---|---|
Observation study | |||
Canaud [24] (Euro-DOPPS-1) Germany, France, Italy, Spain, UK | Prospective obsevation | LFHD 1366 (63%), HFHD 546(25.2%) Low-HDF 156 (7.2%) High-HDF 97 (4.5%) | High-HDF versus LFHD: mortality redaction 35% |
Panichi [25] (RISCAVID), Italy | Prospective obsevation | LFHD 424 (56%) ol-HDF 129 (17.7%) off-HDF 204 (27%) | ol-HDF versus LFHD: mortality redaction 22% |
Vilar [26], UK | Retrospective | HFHD 626 ol-HDF 232(27%) | ol-HDF versus HFHD: mortality redaction 34% |
European Clinical Database (EUCLID) [27], Czech, France, Italy, Portugal, Romania, Spain, Turkey | Retrospective | Post-ol HDF CV < 54.6L/wk versus > 64.8L/wk: 204/204 | CV > 70.1 L/wk:survival 64% increase Survival and CRP/ β2MG reduction depend on CV |
Euro-DOPPS [31] (DOPPS-4,5), Sweden, France, Belgium, Italy, UK, Spain, Germany | Prospective obsevation | Post-ol-HDF versus HD: 2012/6555 | ns |
Kikuchi [32], JRDR, Japan | Retrospective | Pre-ol-HDF ≥ 40L session versus < 40L & HD: 2548/2424/5000 | Pre-ol-HDF ≥ 40L: mortality redaction 29.1% |
Randomized controlled trial (RCT) | |||
Dutch CONTRAST [28], The Netherlands | RCT | Post-ol-HDF versus LFHD: 356/358 | ns, higher CV (> 21.95L):reduction 38% |
Turkish study [29], Turkey | RCT | Post-ol-HDF versus HFHD: 391/391 | ns, higher CV (> 17.4L): mortality reduction 46% |
ESHOL study [20], Spain | RCT | Post-ol-HDF versus HFHD: 450/456 | Mortality Reduction 30%, higher CV (23-25L): 40%, CV (> 25L): 45% |
French study [30], France | RCT | Post-ol-HDF versus HFHD, > 65y.o: 190/191 | ns |